Авторлор жөнүндө
Осмонбеков Мирбек Доолотович, клинический фармаколог, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Сагындыкова Саадат Орозбековна, координатор по лекарственному обеспечению, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Кушубаков Данил Амантурович, врач фтизиортопед, отделения костной хирургии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика,
Тункатарова Жазгуль Кемелбековна, координатор по лекарственному обеспечению, отдел информатики и эпидемиологии Национального центра фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Сулайманова Меркинай Исаевна, к.м.н., специалист по лекарственному менеджменту Проекта USAID "Вылечить туберкулез", Бишкек, Кыргызская Республика
Osmonbekov Mirbek Doolotovich, Clinical Pharmacologist, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Sagyndykova Saadat Orozbekovna, Drug Supply Coordinator, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Kushubakov Danil Amanturovich, phthisiortopedin, Department of Bone Surgery, National Phthisiology Center, Ministry of Health, Bishkek, Kyrgyz Republic,
Tunkatarova Zhazgul Kemelbekovna, Drug Supply Coordinator, Department of Informatics and Epidemiology, National Center for Phthisiology, Ministry of Health, Bishkek, Kyrgyz Republic
Sulaymanova Merkinay Isaevna, Ph.D., Drug Management Specialist, USAID Cure Tuberculosis Project, Bishkek, Kyrgyz Republic
Осмонбеков Мирбек Доолотович, клиникалык фармаколог Улуттук фтизиатрия борборунун, информатика жана эпидемиология бөлүмү,Бишкек Кыргыз Республикасы
Сагындыкова Саадат Орозобековна, дары менен камсыздоо координатору Улуттук фтизиатрия борбору, информатика жана эпидемиология бөлүмү, Бишкек Кыргыз Республикасы
Кушубаков Данил Амантурович, Фтизиортопед дарыгери Улуттук фтизиатрия борбору, сөөк хирургия бөлүмү, Бишкек Кыргыз Республикасы
Тункатарова Жазгуль Кемелбековна, дары менен камсыздоо координатору Улуттук фтизиатрия борбору, информатика жана эпидемиология бөлүмү, Бишкек Кыргыз Республикасы
Сулайманова Меркинай Исаевна, медицина илимдеринин кандидаты, дары боюнча башкаруу боюнча адиси
USAID “Кургак учукту айыктыруу” долбоору, Бишкек Кыргыз Республикасы
Шилтемелер
1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)
1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)
1. World Health Organization. WHO report on the global elimination of tuberculosis 2020. Geneva: WHO; 2020.
2. Practical guide to pharmacovigilance of anti-TB drugs, Improving the safety of TB patients, WHO, 2012
3. Daphne E. Smith Marsh, PharmD, BC-ADM, CDCES, University of Illinois at Chicago College of Pharmacy 04. 2021
4. Pirmohamed M. et al. // British Medical Journal 329:15-19. 2004.
5. Patel KJ et al BMC Clinical Pharmacology volume 7, Article: 8, 2007.
6. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation WHO/HTM/TB/2015.28) [Internet] Geneva, World Health Organization; 2015.
7. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04) [Internet]. Geneva, WHO. 2016.
8. WHO library cataloguing-in-publication data global tuberculosis report 2015. Geneva: World Health Organization; 2015.
9. Chimeh RA, Gafar F,Pradipta IS, Akkerman CW, Hak E, Alffenaar JC,et al. Directly Observed Therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;29(5)
10. Borua CG, Shimelsb T, Bilal AI. Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda,Gurage zone, southern Ethiopia: a qualitative study. J Infect Public Health. 2017;10(5).
11. Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reducedrug resistant tuberculosis? BMC Public Health 2011;
12. Gebremariam MK, Bjune G, Frich JC. Barriers and facilitators of adherence toTB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;
13. Challenges in tuberculosis drug research and development. Ann M Ginsberg & Melvin Spigelman. Nature Medicine volume 13, p.290–294 (2007)
